Home › Calculator › GLPGF Dividend Calculator 2026
GLPGF Dividend DRIP Calculator 2026
7.12% YieldHealthcareLakefront Biotherapeutics · OTC
Price: $28.08 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When GLPGF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your GLPGF snowball 📈
$10,000 in GLPGF → $10.99M in 10 years · $63.67/month
About Lakefront Biotherapeutics (GLPGF) — Dividend Analysis 2026
Galapagos N.V. is a fully-integrated biopharmaceutical firm dedicated to discovering, developing, and bringing to market innovative therapies for conditions where patient needs are largely unaddressed. The company boasts a robust pipeline of investigational drugs, prominently featuring: Filgotinib: A potent JAK1 inhibitor, currently undergoing multiple phases of clinical evaluation for a broad spectrum of inflammatory and autoimmune disorders, such as rheumatoid arthritis, Crohn's disease (including small bowel and fistulizing forms), ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis. GLPG1972: This key candidate has successfully completed its Phase 2b trial targeting osteoarthritis. Toledo Molecules: A series of these molecules (GLPG3970, GLPG4399, and GLPG4876) are under development with a focus on inflammatory conditions. GLPG4716 and Ziritaxestat: These compounds are being advanced to combat idiopathic pulmonary fibrosis. GLPG2737: Further diversifying the portfolio, this cystic fibrosis transmembrane conductance regulator (CFTR) modulator is currently in Phase 2 clinical trials for patients suffering from autosomal dominant polycystic kidney disease. GLPG0555: Moreover, this other JAK1 inhibitor is progressing through Phase 1b development for the management of osteoarthritis. Galapagos N.V. also maintains strategic collaboration agreements with prominent pharmaceutical partners, including Gilead Sciences, Inc., AbbVie S.à r.l., and Novartis Pharma AG. Established in 1999, the company operates from its headquarters in Mechelen, Belgium.
Compare GLPGF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full GLPGF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open GLPGF position with:
🌍 GLPGF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold GLPGF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 7.12% | 4.32% | $712 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 6.05% | 3.25% | $605 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 5.70% | 2.90% | $570 / yr |
| 🇬🇧 UK ISA | 0% | 7.12% | 4.32% | $712 / yr |
| 🇬🇧 UK Taxable | 8.75% | 6.50% | 3.70% | $650 / yr |
| 🇨🇦 TFSA | 0% | 7.12% | 4.32% | $712 / yr |
| 🇨🇦 CA Taxable | 25% | 5.34% | 2.54% | $534 / yr |
| 🇦🇺 Super (pension) | 15% | 6.05% | 3.25% | $605 / yr |
| 🇦🇺 AU Taxable | 30% | 4.98% | 2.18% | $498 / yr |
| 🇩🇪 DE Taxable | 26.375% | 5.24% | 2.44% | $524 / yr |
| 🇫🇷 FR Taxable | 30% | 4.98% | 2.18% | $498 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 GLPGF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 GLPGF Dividend Payment Schedule
GLPGF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 GLPGF vs Healthcare Benchmarks
How GLPGF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for GLPGF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ GLPGF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where GLPGF earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the GLPGF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Lakefront Biotherapeutics (GLPGF) is currently trading at $28.08, 73% below its 52-week high. The current dividend yield is 7.12% based on an annual payout of $2.00 per share.
GLPGF (Lakefront Biotherapeutics) — 7.12% Dividend Yield Analysis
Lakefront Biotherapeutics (GLPGF) is a healthcare stock currently trading at $28.08 with a dividend yield of 7.12%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (7.12%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.